Biogen Partners With LigoCyte On Anti-CD103 Target
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies will pursue development of treatments for respiratory, gastrointestinal and autoimmune indications.
You may also be interested in...
Biogen Idec Partners With Cardiokine On Vasopressin Antagonist For Hyponatremia
Phase III trials of the oral drug, which will start this year, are expected to take two years to complete, Biogen says.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.